Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China

References

• World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Technical Guidance Group of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis epidemiological survey in 2010. Chinese Journal of Antituberculosis. 2012;34(8):485–508.
   Google Scholar
• Li Z, Yang Y. Rheumatology in China: challenges and development. Rheumatology (Oxford). 2012;51(10):1733–1734.
   Web of Science ®Google Scholar
• Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10(1):R17.
   PubMed Web of Science ®Google Scholar
• Wang D, Ma L. The review analysis of Chinese systemic lupus erythematosus patients complicated with tuberculosis infection. Chinese Journal of Rheumatology. 2009;13(9):599–602.
   Google Scholar
• Cheng CF, Huang YM, Lu CH, et al. Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study. Lupus. 2019;28(14):1699–1704.
   PubMed Web of Science ®Google Scholar
• WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
   Google Scholar
• Zeng QZ, Zhang YY, Wu YJ, et al. Frequency, risk factors, and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(6):1203–1209.
   Web of Science ®Google Scholar
• Expert Recommendation Group for Tuberculosis Prevention and Management in the Use of TNF Antagonists. Expert consensus on prevention and management of tuberculosis infection in tumor necrosis factor antagonist application. Chin J Rheumatol. 2013;17(8):508–512.
   Google Scholar
• Park DW, Chung SJ, Yeo Y, et al. Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. J Thorac Dis. 2019;11(11):4573–4582.
   Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–722.
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in quebec, Canada. Arthritis Rheum. 2009;61(3):300–304.
   PubMedGoogle Scholar
• Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19–26.
   PubMed Web of Science ®Google Scholar
• Lai CC, Lee MT, Lee SH, et al. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015;19(8):936–942.
   PubMed Web of Science ®Google Scholar
• Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70(7):677–682.
   PubMed Web of Science ®Google Scholar
• Zeng SY, Gong Y, Zhang YP, et al. Changes in the prevalence of rheumatic diseases in shantou, China, in the past three decades: A COPCORD study. PLoS One. 2015;10(9):e0138492.
   Web of Science ®Google Scholar
• Commission PsRoCshaFP. Tuberculosis classification (WS196–2017). Electronic Journal of Emerging Infectious Diseases. 2018;3(3):191–192.
   Google Scholar
• Yang Y, Thumboo J, Tan BH, et al. The risk of tuberculosis in SLE patients from an asian tertiary hospital. Rheumatol Int. 2017;37(6):1027–1033.
   PubMed Web of Science ®Google Scholar
• Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from southern China: a retrospective study. Clin Rheumatol. 2019;38(2):535–543.
   Web of Science ®Google Scholar
• Gonzalez-Naranjo LA, Coral-Enriquez JA, Restrepo-Escobar M, et al. Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study. Clin Rheumatol. 2021;40(1):181–191.
   Web of Science ®Google Scholar
• Torres-Gonzalez P, Romero-Diaz J, Cervera-Hernandez ME, et al. Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico city. Clin Rheumatol. 2018;37(8):2095–2102.
   PubMed Web of Science ®Google Scholar
• Juarez V, Quintana R, Crespo ME, et al. Prevalence of musculoskeletal disorders and rheumatic diseases in an argentinean indigenous wichi community. Clin Rheumatol. 2021;40(1):75–83.
   Web of Science ®Google Scholar
• Liu Y, Zhang L, Zhou Z, et al. Clinical features and risk factors of active tuberculosis in patients with Behcet's disease. J Immunol Res. 2020;2020:2528676.
   Web of Science ®Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229–2237.
   PubMed Web of Science ®Google Scholar
• Efthimiou J, Hay PE, Spiro SG, et al. Pulmonary tuberculosis in Behcet's syndrome. Br J Dis Chest. 1988;82(3):300–304.
   Google Scholar
• Freitas SM, Marques JS, Grilo A, et al. Behcet's disease and tuberculosis: A complex relationship. Eur J Case Rep Intern Med. 2020;7(2):001354.
   Google Scholar
• Galeone M, Colucci R, D'Erme AM, et al. Potential Infectious etiology of Behcet's disease. Patholog Res Int. 2012;2012:595380.
   PubMedGoogle Scholar
• Ramagopalan SV, Goldacre R, Skingsley A, et al. Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med. 2013;11:97.
   PubMed Web of Science ®Google Scholar
• Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid Use. Rheum Dis Clin North Am. 2016;42(1):157–176., ix-x.
   PubMed Web of Science ®Google Scholar
• Fortes FML, Sorte NB, Mariano VD, et al. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America. World J Gastroenterol. 2020;26(44):6993–7004.
   Web of Science ®Google Scholar
• Guirao-Arrabal E, Santos F, Redel-Montero J, et al. Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use. Transpl Infect Dis. 2016;18(4):512–519.
   Web of Science ®Google Scholar
• Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med. 2014;46(7):547–554.
   PubMed Web of Science ®Google Scholar
• Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol. 2001;39(6):2213–2218.
   PubMed Web of Science ®Google Scholar
• Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004;170(12):1360–1366.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–1693.
   PubMed Web of Science ®Google Scholar